Industry News
Pharmaceutical Industry News
Despite a prolonged period of…
Despite a prolonged period of policy uncertainty in the U.S.—and the ripple effects across the global life sciences and healthcare industries—executives at health companies are still seeing opportunities amid the tumult.
Medicare Coverage for GLP-1 Weight Loss Drugs: Cost, Eligibility and What to Know
What you should know about the federal government’s pilot program offering GLP-1s solely for weight loss.
The Strange Alliance Trying to Remake American Psychiatry
The Department of Health and critical psychiatry activists are hoping to upend 40 years of medical orthodoxy.
As biologics have increasingly…
As biologics have increasingly superseded small molecules in the biopharma industry’s pipeline, the mounting complexity of their manufacturing products is putting production and launches under pressure.
BridgeBio Pharma is teaming up…
BridgeBio Pharma is teaming up with BlackDoctor and HealthyWomen to highlight how the heart condition ATTR-cardiac amyloidosis (ATTR-CM) is being “systematically missed in women.”
Supreme Court Allows Abortion Pill Access by Mail to Continue
A federal appeals court ruling against the Food and Drug Administration would have restricted access by mail to mifepristone.
To secure an exemption from 100%…
To secure an exemption from 100% tariffs on imported drugs to the U.S., companies that have not made MFN pricing deals with the government will be required to provide detailed information on their investment and
Doceree has bold ambitions to…
Doceree has bold ambitions to bring to a new software category to pharma brand teams, one that reshapes campaign deployment in the artificial intelligence era.
Eli Lilly has made a six-year, $50…
Eli Lilly has made a six-year, $50 million commitment to UNICEF USA to support efforts to improve the prevention, detection and management of noncommunicable diseases.
PharmaForceIQ’s Derek Choy…
PharmaForceIQ’s Derek Choy explains how data, real-time signals, and optimizing for share of answer are reshaping how pharma brands engage HCPs and patients.
Following an FDA approval in…
Following an FDA approval in muscle-invasive bladder cancer patients who are eligible to receive cisplatin-based chemotherapy, AstraZeneca on Thursday reported positive phase 3 results for its Imfinzi, used alongside Padcev, in those who were cisplatin-ineligible.
With the FDA now rudderless…
With the FDA now rudderless following the revelation that commissioner Marty Makary, M.D., is stepping down, voices across biopharma have joined in support of the FDA’s former top drug regulator Richard Pazdur, M.D., as President
BMS and Hengrui signed a massive…
BMS and Hengrui signed a massive deal worth up to $15.2 billion. Takeda aims to cut 4,500 jobs in fiscal 2026. Daiichi Sankyo aims to be a global top-5 oncology player while expanding beyond antibody-drug
AI search is collapsing the health…
AI search is collapsing the health info funnel. Learn how GEO determines whether your brand is the answer—or invisible.
The framework would leverage…
The framework would leverage existing safety data on approved drugs to provide new options to patients with unmet medical needs, the FDA explained.
Generics juggernaut Sun Pharma is…
Generics juggernaut Sun Pharma is pulling one lot of a chemotherapy drug in the United States as the issue of particulate contamination crops up once again on the FDA’s recall register.
Taiwan’s Bora Group will shell…
Taiwan’s Bora Group will shell out up to $127.5 million to acquire the CDMO business and manufacturing operations from Maryland-based MacroGenics.
Purdue Pharma Is Gone. What Comes Next Could Be Worse.
The Purdue Pharma case is closed, but the opioid problem remains.
BeOne Medicines has entered the…
BeOne Medicines has entered the BCL-2 arena, securing an FDA green light for Beqalzi that carves out a unique piece of territory ahead of a potential broader clash with market leader Venclexta.
How privacy-first data and…
How privacy-first data and data-driven TV are helping pharma brands cut waste and reach real patients.